The novel Parkinson's disease linked mutation G51D attenuates in vitro aggregation and membrane binding of α-synuclein, and enhances its secretion and nuclear localization in cells

Human Molecular Genetics

Volumn 23, Issue 17, 2014, Pages 4491-4509

  Fares, Mohamed Bilal ^a   Ait Bouziad, Nadine ^a   Dikiy, Igor ^b   Mbefo, Martial K ^a   Jovičić, Ana ^c   Kiely, Aoife ^d   Holton, Janice L ^d   Lee, Seung Jae ^e   Gitler, Aaron D ^c   Eliezer, David ^b   Lashuel, Hilal A ^a  

^a EPFL   (Switzerland)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e Konkuk University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; BUFFER; DODECYL SULFATE SODIUM; LIPOSOME; PROTEIN AGGREGATE; PROTEIN BINDING;

BRAIN; CELL CULTURE; CELL DIFFERENTIATION; CELL FRACTIONATION; CELL INCLUSION; CELL LINE; CELL MEMBRANE; CELL NUCLEUS; CELL NUCLEUS MEMBRANE; CHEMISTRY; DRUG EFFECTS; GENETICS; HUMAN; METABOLISM; MITOCHONDRION; MUTATION; NERVE CELL; NEUROBLASTOMA; PARKINSON DISEASE; PATHOLOGY; PHOSPHORYLATION; PROTEIN SECONDARY STRUCTURE; PROTEIN TRANSPORT; PROTEINOSIS; SACCHAROMYCES CEREVISIAE; SECRETION (PROCESS); ULTRASTRUCTURE;

ALPHA-SYNUCLEIN; BRAIN; BUFFERS; CELL DIFFERENTIATION; CELL LINE; CELL MEMBRANE; CELL NUCLEUS; CELLS, CULTURED; HUMANS; INCLUSION BODIES; MITOCHONDRIA; MUTATION; NEUROBLASTOMA; NEURONS; NUCLEAR ENVELOPE; PARKINSON DISEASE; PHOSPHORYLATION; PROTEIN AGGREGATES; PROTEIN AGGREGATION, PATHOLOGICAL; PROTEIN BINDING; PROTEIN STRUCTURE, SECONDARY; PROTEIN TRANSPORT; SACCHAROMYCES CEREVISIAE; SODIUM DODECYL SULFATE; SUBCELLULAR FRACTIONS; UNILAMELLAR LIPOSOMES;

EID: 84901338303     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddu165     Document Type: Article

References (104)

1. Goedert, M., Spillantini, M.G., Del Tredici, K. and Braak, H. (2013) 100 years of Lewy pathology. Nat. Rev. Neurol., 9, 13-24.
2. Polymeropoulos, M.H., Lavedan, C., Leroy, E., Ide, S.E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R. et al. (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science, 276, 2045-2047.
3. Baba, M., Nakajo, S., Tu, P.H., Tomita, T., Nakaya, K., Lee, V.M., Trojanowski, J.Q. and Iwatsubo, T. (1998) Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. Am. J. Pathol., 152, 879-884.
4. Lashuel, H.A., Overk, C.R., Oueslati, A. and Masliah, E. (2013) The many faces of alpha-synuclein: from structure and toxicity to therapeutic target. Nat. Rev. Neurosci., 14, 38-48.
5. Bendor, J.T., Logan, T.P. and Edwards, R.H. (2013) The function of alphasynuclein. Neuron, 79, 1044-1066.
6. Weinreb, P.H., Zhen, W., Poon, A.W., Conway, K.A. and Lansbury, P.T. Jr. (1996) NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded. Biochemistry, 35, 13709-13715.
7. Eliezer,D.,Kutluay,E.,Bussell,R. Jr. andBrowne, G. (2001) Conformational properties of alpha-synuclein in its free and lipid-associated states. J. Mol. Biol., 307, 1061-1073.
8. Davidson, W.S., Jonas, A., Clayton, D.F. and George, J.M. (1998) Stabilization of alpha-synuclein secondary structure upon binding to synthetic membranes. J. Biol. Chem., 273, 9443-9449.
9. Ahn, K.J., Paik, S.R., Chung, K.C. and Kim, J. (2006) Amino acid sequence motifs and mechanistic features of the membrane translocation of alpha-synuclein. J. Neurochem., 97, 265-279.
10. Ulmer, T.S., Bax, A., Cole, N.B. and Nussbaum, R.L. (2005) Structure and dynamics of micelle-bound human alpha-synuclein. J. Biol. Chem., 280, 9595-9603.
11. Lansbury, P.T. Jr., Costa, P.R., Griffiths, J.M., Simon, E.J., Auger, M., Halverson, K.J., Kocisko, D.A., Hendsch, Z.S., Ashburn, T.T., Spencer, R.G. et al. (1995) Structural model for the beta-amyloid fibril based on interstrand alignment of an antiparallel-sheet comprising a C-terminal peptide. Nat. Struct. Biol., 2, 990-998.
12. Singleton, A.B., Farrer, M., Johnson, J., Singleton, A., Hague, S., Kachergus, J., Hulihan, M., Peuralinna, T., Dutra, A., Nussbaum, R. et al. (2003) alpha-Synuclein locus triplication causes Parkinson's disease. Science, 302, 841.
13. Chartier-Harlin, M.C., Kachergus, J., Roumier, C., Mouroux, V., Douay, X., Lincoln, S., Levecque, C., Larvor, L., Andrieux, J., Hulihan, M. et al. (2004) Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet, 364, 1167-1169.
14. Kruger, R., Kuhn, W., Muller, T., Woitalla, D., Graeber, M., Kosel, S., Przuntek, H., Epplen, J.T., Schols, L. and Riess, O. (1998) Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat. Genet., 18, 106-108.
15. Zarranz, J.J., Alegre, J., Gomez-Esteban, J.C., Lezcano, E., Ros, R., Ampuero, I., Vidal, L., Hoenicka, J., Rodriguez, O., Atares, B. et al. (2004) The new mutation, E46 K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann. Neurol., 55, 164-173.
16. Appel-Cresswell, S., Vilarino-Guell, C., Encarnacion, M., Sherman, H., Yu, I., Shah, B., Weir, D., Thompson, C., Szu-Tu, C., Trinh, J. et al. (2013) Alpha-synuclein p.H50Q, a novel pathogenic mutation for Parkinson's disease. Mov. Disord., 28, 811-813.
17. Kiely, A.P., Asi, Y.T., Kara, E., Limousin, P., Ling, H., Lewis, P., Proukakis, C., Quinn, N., Lees, A.J., Hardy, J. et al. (2013) alpha-Synucleinopathy associated with G51D SNCA mutation: a link between Parkinson's disease and multiple system atrophy? Acta Neuropathol., 125, 753-769.
18. Lesage, S., Anheim, M., Letournel, F., Bousset, L., Honore, A., Rozas, N., Pieri, L., Madiona, K., Durr, A., Melki, R. et al. (2013) G51D alpha-synuclein mutation causes a novel parkinsonian-pyramidal syndrome. Ann. Neurol., 73, 459-471.
19. Ghosh, D., Mondal, M., Mohite, G.M., Singh, P.K., Ranjan, P., Anoop, A., Ghosh, S., Jha, N.N., Kumar, A. and Maji, S.K. (2013) The Parkinson's disease-associated H50Q mutation accelerates alpha-Synuclein aggregation in vitro. Biochemistry, 52, 6925-6927.
20. Bussell, R. Jr. and Eliezer, D. (2003) A structural and functional role for 11-mer repeats in alpha-synuclein and other exchangeable lipid binding proteins. J. Mol. Biol., 329, 763-778.
21. Chandra, S., Chen, X., Rizo, J., Jahn, R. and Sudhof, T.C. (2003) A broken alpha -helix in folded alpha-Synuclein. J. Biol. Chem., 278, 15313-15318.
22. Borbat, P., Ramlall, T.F., Freed, J.H. and Eliezer, D. (2006) Inter-helix distances in lysophospholipid micelle-bound alpha-synuclein from pulsed ESR measurements. J. Am. Chem. Soc., 128, 10004-10005.
23. Bussell, R. Jr. and Eliezer, D. (2004) Effects of Parkinson's disease-linked mutations on the structure of lipid-associated alpha-synuclein. Biochemistry, 43, 4810-4818.
24. Bodner, C.R., Dobson, C.M. and Bax, A. (2009) Multiple tight phospholipid-binding modes of alpha-synuclein revealed by solutionNMR spectroscopy. J. Mol. Biol., 390, 775-790.
25. Rizo, J., Blanco, F.J., Kobe, B., Bruch, M.D. and Gierasch, L.M. (1993) Conformational behavior of Escherichia coli OmpA signal peptides in membrane mimetic environments. Biochemistry, 32, 4881-4894.
26. Bodner, C.R., Maltsev, A.S., Dobson, C.M. and Bax, A. (2010) Differential phospholipid binding of alpha-synuclein variants implicated in Parkinson's disease revealed by solution NMR spectroscopy. Biochemistry, 49, 862-871.
27. Drescher,M.,Godschalk, F.,Veldhuis, G., vanRooijen,B.D.,Subramaniam, V. and Huber,M. (2008) Spin-label EPR on alpha-synuclein reveals differences in the membrane binding affinity of the two antiparallel helices. Chembiochem, 9, 2411-2416.
28. Bartels, T., Ahlstrom, L.S., Leftin, A., Kamp, F., Haass, C., Brown, M.F. and Beyer, K. (2010) The N-terminus of the intrinsically disordered protein alpha-synuclein triggers membrane binding and helix folding. Biophys. J., 99, 2116-2124.
29. Anderson, V.L., Ramlall, T.F., Rospigliosi, C.C., Webb,W.W.and Eliezer, D. (2010) Identification of a helical intermediate in trifluoroethanol induced alpha-synuclein aggregation. Proc. Natl Acad. Sci. USA, 107, 18850-18855.
30. Uversky, V.N., Li, J. and Fink, A.L. (2001) Evidence for a partially folded intermediate in alpha-synuclein fibril formation. J. Biol. Chem., 276, 10737-10744.
31. Outeiro, T.F. and Lindquist, S. (2003) Yeast cells provide insight into alpha-synuclein biology and pathobiology. Science, 302, 1772-1775.
32. Willingham, S., Outeiro, T.F., DeVit, M.J., Lindquist, S.L. and Muchowski, P.J. (2003) Yeast genes that enhance the toxicity of a mutant huntingtin fragment or alpha-synuclein. Science, 302, 1769-1772.
33. Cooper, A.A., Gitler, A.D., Cashikar, A., Haynes, C.M., Hill, K.J., Bhullar, B., Liu, K., Xu, K., Strathearn, K.E., Liu, F. et al. (2006) Alpha-synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson's models. Science, 313, 324-328.
34. Gitler, A.D., Bevis, B.J., Shorter, J., Strathearn, K.E., Hamamichi, S., Su, L.J., Caldwell, K.A., Caldwell, G.A., Rochet, J.C., McCaffery, J.M. et al. (2008) The Parkinson's disease protein alpha-synuclein disrupts cellular Rab homeostasis. Proc. Natl Acad. Sci. USA, 105, 145-150.
35. Gitler, A.D., Chesi, A., Geddie, M.L., Strathearn, K.E., Hamamichi, S., Hill, K.J., Caldwell, K.A., Caldwell, G.A., Cooper, A.A., Rochet, J.C. et al. (2009) Alpha-synuclein is part of a diverse and highly conserved interaction network that includes PARK9 and manganese toxicity. Nat. Genet., 41, 308-315.
36. Yeger-Lotem, E., Riva, L., Su, L.J., Gitler, A.D., Cashikar, A.G., King, O.D., Auluck, P.K., Geddie, M.L., Valastyan, J.S., Karger, D.R. et al. (2009) Bridging high-throughput genetic and transcriptional data reveals cellular responses to alpha-synuclein toxicity. Nat. Genet., 41, 316-323.
37. Tardiff, D.F., Jui, N.T., Khurana, V., Tambe, M.A., Thompson, M.L., Chung,C.Y., Kamadurai, H.B.,Kim,H.T., Lancaster, A.K., Caldwell, K.A. et al. (2013) Yeast reveal a druggable Rsp5/Nedd4 network that ameliorates alpha-synuclein toxicity in neurons. Sciencei, 342, 979-983.
38. Bussell, R. Jr. and Eliezer, D. (2001) Residual structure and dynamics in Parkinson's disease-associated mutants of alpha-synuclein. J. Biol. Chem., 276, 45996-46003.
39. Cole, N.B., Murphy, D.D., Grider, T., Rueter, S., Brasaemle, D. and Nussbaum, R.L. (2002) Lipid droplet binding and oligomerization properties of the Parkinson's disease protein alpha-synuclein. J. Biol. Chem., 277, 6344-6352.
40. Jensen, P.H., Nielsen, M.S., Jakes, R., Dotti, C.G. and Goedert, M. (1998) Binding of alpha-synuclein to brain vesicles is abolished by familial Parkinson's disease mutation. J. Biol. Chem., 273, 26292-26294.
41. McKinney, S.A., Murphy, C.S., Hazelwood, K.L., Davidson, M.W. and Looger, L.L. (2009)Abright and photostable photoconvertible fluorescent protein. Nat. Methods, 6, 131-133.
42. Specht, C.G., Tigaret, C.M., Rast, G.F., Thalhammer, A., Rudhard, Y. and Schoepfer, R. (2005) Subcellular localisation of recombinant alpha- and gamma-synuclein. Mol. Cell. Neurosci., 28, 326-334.
43. Ma, K.L., Song, L.K., Yuan, Y.H., Zhang, Y., Han, N., Gao, K. and Chen, N.H. (2013) The nuclear accumulation of alpha-synuclein is mediated by importin alpha and promotes neurotoxicity by accelerating the cell cycle. Neuropharmacology. http://dx.doi.org/10.1016/j.neuropharm.2013.07.035.
44. Goncalves, S. and Outeiro, T.F. (2013) Assessing the subcellular dynamics of alpha-synuclein using photoactivation microscopy. Mol. Neurobiol., 47, 1081-1092.
45. Schell, H., Hasegawa, T., Neumann, M. and Kahle, P.J. (2009) Nuclear and neuritic distribution of serine-129 phosphorylated alpha-synuclein in transgenic mice. Neuroscience, 160, 796-804.
46. Mbefo, M.K., Paleologou, K.E., Boucharaba, A., Oueslati, A., Schell, H., Fournier, M., Olschewski, D., Yin, G., Zweckstetter, M., Masliah, E. et al. (2010) Phosphorylation of synucleins by members of the Polo-like kinase family. J. Biol. Chem., 285, 2807-2822.
47. Wakamatsu, M., Ishii, A., Ukai, Y., Sakagami, J., Iwata, S., Ono, M., Matsumoto, K., Nakamura, A., Tada, N., Kobayashi, K. et al. (2007) Accumulation of phosphorylated alpha-synuclein in dopaminergic neurons of transgenic mice that express human alpha-synuclein. J. Neurosci. Res., 85, 1819-1825.
48. Huang, Z., Xu, Z., Wu, Y. and Zhou, Y. (2011) Determining nuclear localization of alpha-synuclein in mouse brains. Neuroscience, 199, 318-332.
49. Oueslati, A., Fournier, M. and Lashuel, H.A. (2010) Role of post-translational modifications in modulating the structure, function and toxicity of alpha-synuclein: implications for Parkinson's disease pathogenesis and therapies. Prog. Brain Res., 183, 115-145.
50. Sato, H., Arawaka, S., Hara, S., Fukushima, S., Koga, K., Koyama, S. and Kato, T. (2011) Authentically phosphorylated alpha-synuclein at Ser129 accelerates neurodegeneration in a rat model of familial Parkinson's disease. J. Neurosci., 31, 16884-16894.
51. Oueslati, A., Schneider, B.L., Aebischer, P. and Lashuel, H.A. (2013) Polo-like kinase 2 regulates selective autophagic alpha-synuclein clearance and suppresses its toxicity in vivo. Proc. Natl Acad. Sci. USA, 110, E3945-E3954.
52. Esteves, A.R., Arduino, D.M., Silva, D.F., Oliveira, C.R. and Cardoso, S.M. (2011) Mitochondrial dysfunction: the road to alpha-Synuclein oligomerization in PD. Parkinsons Dis., 2011, 693761.
53. Lee, S.J. (2003) alpha-synuclein aggregation: a link between mitochondrial defects and Parkinson's disease? Antioxid Redox Signal, 5, 337-348.
54. Ko, L.W., Ko, H.H., Lin, W.L., Kulathingal, J.G. and Yen, S.H. (2008) Aggregates assembled from overexpression of wild-type alpha-synuclein are not toxic to human neuronal cells. J. Neuropathol. Exp. Neurol., 67, 1084-1096.
55. Cookson, M.R. (2009) alpha-Synuclein and neuronal cell death. Mol. Neurodegener., 4, 9.
56. El-Agnaf, O.M., Salem, S.A., Paleologou, K.E., Cooper, L.J., Fullwood, N.J., Gibson, M.J., Curran, M.D., Court, J.A., Mann, D.M., Ikeda, S. et al. (2003) Alpha-synuclein implicated in Parkinson's disease is present in extracellular biological fluids, including human plasma. FASEB J., 17, 1945-1947.
57. Borghi, R., Marchese, R., Negro, A., Marinelli, L., Forloni, G., Zaccheo, D., Abbruzzese, G. and Tabaton, M. (2000) Full length alpha-synuclein is present in cerebrospinal fluid from Parkinson's disease and normal subjects. Neurosci. Lett., 287, 65-67.
58. Fjorback, A.W., Varming, K. and Jensen, P.H. (2007) Determination of alpha-synuclein concentration in human plasma using ELISA. Scand. J. Clin. Lab. Invest., 67, 431-435.
59. Kasuga, K., Nishizawa, M. and Ikeuchi, T. (2012) alpha-Synuclein as CSF and blood biomarker of dementia with Lewy bodies. Int. J. Alzheimer Dis., 2012, 437025.
60. Tinsley, R.B., Kotschet, K., Modesto, D., Ng, H., Wang, Y., Nagley, P., Shaw, G. and Horne, M.K. (2010) Sensitive and specific detection of alpha-synuclein in human plasma. J. Neurosci. Res., 88, 2693-2700.
61. Devic, I., Hwang, H., Edgar, J.S., Izutsu, K., Presland, R., Pan, C., Goodlett, D.R., Wang, Y., Armaly, J., Tumas, V. et al. (2011) Salivary alpha-synuclein and DJ-1: potential biomarkers for Parkinson's disease. Brain, 134, e178.
62. Cersosimo, M.G., Perandones, C., Micheli, F.E., Raina, G.B., Beron, A.M., Nasswetter, G., Radrizzani, M. and Benarroch, E.E. (2011) Alpha-synuclein immunoreactivity in minor salivary gland biopsies of Parkinson's disease patients. Mov. Disord., 26, 188-190.
63. Desplats, P., Lee, H.J., Bae, E.J., Patrick, C., Rockenstein, E., Crews, L., Spencer, B., Masliah, E. and Lee, S.J. (2009) Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein. Proc. Natl Acad. Sci. USA, 106, 13010-13015.
64. Emmanouilidou, E., Stefanis, L. and Vekrellis, K. (2010) Cell-produced alpha-synuclein oligomers are targeted to, and impair, the 26S proteasome. Neurobiol. Aging, 31, 953-968.
65. Lee, H.J., Patel, S. and Lee, S.J. (2005) Intravesicular localization and exocytosis of alpha-synuclein and its aggregates. J. Neurosci., 25, 6016-6024.
66. Lee, H.J., Suk, J.E., Bae, E.J. and Lee, S.J. (2008) Clearance and deposition of extracellular alpha-synuclein aggregates in microglia. Biochem. Biophys. Res. Commun., 372, 423-428.
67. Li, J., Uversky, V.N. and Fink, A.L. (2001) Effect of familial Parkinson's disease point mutations A30P and A53 T on the structural properties, aggregation, and fibrillation of human alpha-synuclein. Biochemistry, 40, 11604-11613.
68. Giasson, B.I., Uryu, K., Trojanowski, J.Q. and Lee, V.M. (1999) Mutant and wild type human alpha-synucleins assemble into elongated filaments with distinct morphologies in vitro. J. Biol. Chem., 274, 7619-7622.
69. Conway, K.A., Lee, S.J., Rochet, J.C., Ding, T.T., Williamson, R.E. and Lansbury, P.T. Jr. (2000) Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. Proc. Natl Acad. Sci. USA, 97, 571-576.
70. Georgieva, E.R., Ramlall, T.F., Borbat, P.P., Freed, J.H. and Eliezer, D. (2008) Membrane-bound alpha-synuclein forms an extended helix: long-distance pulsed ESR measurements using vesicles, bicelles, and rodlike micelles. J. Am. Chem. Soc., 130, 12856-12857.
71. Jao, C.C., Hegde, B.G., Chen, J., Haworth, I.S. and Langen, R. (2008) Structure of membrane-bound alpha-synuclein from site-directed spin labeling and computational refinement. Proc. Natl Acad. Sci. USA, 105, 19666-19671.
72. Dikiy, I. and Eliezer, D. (2012) Folding and misfolding of alpha-synuclein on membranes. Biochim. Biophys. Acta, 1818, 1013-1018.
73. Georgieva, E.R., Ramlall, T.F., Borbat, P.P., Freed, J.H. and Eliezer, D. (2010) The lipid-binding domain of wild type and mutant alpha-synuclein: compactness and interconversion between the broken and extended helix forms. J. Biol. Chem., 285, 28261-28274.
74. Asi, Y.T., Simpson, J.E., Heath, P.R., Wharton, S.B., Lees, A.J., Revesz, T., Houlden, H. and Holton, J.L. (2014) Alpha-synuclein mRNA expression in oligodendrocytes in MSA. Glia., 62, 964-970.
75. Reyes, J.F., Rey, N.L., Bousset, L., Melki, R., Brundin, P. and Angot, E. (2014) Alpha-synuclein transfers from neurons to oligodendrocytes. Glia, 62, 387-398.
76. Maroteaux, L., Campanelli, J.T. and Scheller, R.H. (1988) Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal. J. Neurosci., 8, 2804-2815.
77. Abeliovich, A., Schmitz, Y., Farinas, I., Choi-Lundberg, D., Ho, W.H., Castillo, P.E., Shinsky, N., Verdugo, J.M., Armanini, M., Ryan, A. et al. (2000) Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron, 25, 239-252.
78. Chandra, S., Gallardo, G., Fernandez-Chacon, R., Schluter, O.M. and Sudhof, T.C. (2005) Alpha-synuclein cooperates with CSPalpha in preventing neurodegeneration. Cell, 123, 383-396.
79. Totterdell, S. and Meredith, G.E. (2005) Localization of alpha-synuclein to identified fibers and synapses in the normal mouse brain. Neuroscience, 135, 907-913.
80. Lee, S.J., Jeon, H. and Kandror, K.V. (2008) Alpha-synuclein is localized in a subpopulation of rat brain synaptic vesicles. Acta. Neurobiol. Exp. (Wars), 68, 509-515.
81. Watson, J.B., Hatami, A., David, H., Masliah, E., Roberts, K., Evans, C.E. and Levine, M.S. (2009) Alterations in corticostriatal synaptic plasticity in mice overexpressing human alpha-synuclein. Neuroscience, 159, 501-513.
82. Yu, S., Li, X., Liu, G., Han, J., Zhang, C., Li, Y., Xu, S., Liu, C., Gao, Y., Yang, H. et al. (2007) Extensive nuclear localization of alpha-synuclein in normal rat brain neurons revealed by a novel monoclonal antibody. Neuroscience, 145, 539-555.
83. Zhang, L., Zhang, C., Zhu, Y., Cai, Q., Chan, P., Ueda, K., Yu, S. and Yang, H. (2008) Semi-quantitative analysis of alpha-synuclein in subcellular pools of rat brain neurons: an immunogold electron microscopic study using a C-terminal specific monoclonal antibody. Brain Res., 1244, 40-52.
84. Vivacqua, G., Yin, J.J., Casini, A., Li, X., Li, Y.H., D'Este, L., Chan, P., Renda, T.G. and Yu, S. (2009) Immunolocalization of alpha-synuclein in the rat spinal cord by two novel monoclonal antibodies. Neuroscience, 158, 1478-1487.
85. Zhong, S.C., Luo, X., Chen, X.S., Cai, Q.Y., Liu, J., Chen, X.H. and Yao, Z.X. (2010) Expression and subcellular location of alpha-synuclein during mouse-embryonic development. Cell Mol. Neurobiol., 30, 469-482.
86. Xu, S., Zhou, M., Yu, S., Cai, Y., Zhang, A., Ueda, K. and Chan, P. (2006) Oxidative stress induces nuclear translocation of C-terminus of alpha-synuclein in dopaminergic cells. Biochem. Biophys. Res. Commun., 342, 330-335.
87. Zhou, M., Xu, S., Mi, J., Ueda, K. and Chan, P. (2013) Nuclear translocation of alpha-synuclein increases susceptibility of MES23.5 cells to oxidative stress. Brain Res., 1500, 19-27.
88. Kontopoulos, E., Parvin, J.D. and Feany, M.B. (2006) Alpha-synuclein acts in the nucleus to inhibit histone acetylation and promote neurotoxicity. Hum. Mol. Genet., 15, 3012-3023.
89. Klement, I.A., Skinner, P.J., Kaytor, M.D., Yi, H., Hersch, S.M., Clark, H.B., Zoghbi, H.Y. and Orr, H.T. (1998) Ataxin-1 nuclear localization and aggregation: role in polyglutamine-induced disease in SCA1 transgenic mice. Cell, 95, 41-53.
90. Saudou, F., Finkbeiner, S., Devys, D. and Greenberg, M.E. (1998) Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell, 95, 55-66.
91. Peters, M.F., Nucifora, F.C. Jr., Kushi, J., Seaman, H.C., Cooper, J.K., Herring, W.J., Dawson, V.L., Dawson, T.M. and Ross, C.A. (1999) Nuclear targeting of mutant Huntingtin increases toxicity. Mol. Cell. Neurosci., 14, 121-128.
92. Takeyama, K., Ito, S., Yamamoto, A., Tanimoto, H., Furutani, T., Kanuka, H., Miura, M., Tabata, T. and Kato, S. (2002) Androgen-dependent neurodegeneration by polyglutamine-expanded human androgen receptor in Drosophila. Neuron, 35, 855-864.
93. Goers, J., Manning-Bog, A.B., McCormack, A.L., Millett, I.S., Doniach, S., Di Monte, D.A., Uversky, V.N. and Fink, A.L. (2003) Nuclear localization of alpha-synuclein and its interaction with histones. Biochemistry, 42, 8465-8471.
94. Siddiqui, A., Chinta, S.J., Mallajosyula, J.K., Rajagopolan, S., Hanson, I., Rane, A., Melov, S. and Andersen, J.K. (2012) Selective binding of nuclear alpha-synuclein to the PGC1alpha promoter under conditions of oxidative stress may contribute to losses in mitochondrial function: implications for Parkinson's disease. Free Radic. Biol. Med., 53, 993-1003.
95. Anderson, J.P., Walker, D.E., Goldstein, J.M., de Laat, R., Banducci, K., Caccavello, R.J., Barbour, R., Huang, J., Kling, K., Lee, M. et al. (2006) Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease. J. Biol. Chem., 281, 29739-29752.
96. Emmer, K.L., Waxman, E.A., Covy, J.P. and Giasson, B.I. (2011) E46 K human alpha-synuclein transgenic mice develop Lewy-like and tau pathology associated with age-dependent, detrimental motor impairment. J. Biol. Chem., 286, 35104-35118.
97. Smith, W.W., Margolis, R.L., Li, X., Troncoso, J.C., Lee, M.K., Dawson, V.L., Dawson, T.M., Iwatsubo, T. and Ross, C.A. (2005) Alpha-synuclein phosphorylation enhances eosinophilic cytoplasmic inclusion formation in SH-SY5Y cells. J. Neurosci., 25, 5544-5552.
98. Ishii, A., Nonaka, T., Taniguchi, S., Saito, T., Arai, T., Mann, D., Iwatsubo, T., Hisanaga, S., Goedert, M. and Hasegawa, M. (2007) Casein kinase 2 is the major enzyme in brain that phosphorylates Ser129 of human alpha-synuclein: Implication for alpha-synucleinopathies.FEBSLett., 581, 4711-4717.
99. Wakamatsu, M., Ishii, A., Iwata, S., Sakagami, J., Ukai, Y., Ono, M., Kanbe, D., Muramatsu, S., Kobayashi, K., Iwatsubo, T. et al. (2008) Selective loss of nigral dopamine neurons induced by overexpression of truncated human alpha-synuclein in mice. Neurobiol. Aging, 29, 574-585.
100. Marley, J., Lu, M. and Bracken, C. (2001) A method for efficient isotopic labeling of recombinant proteins. J. Biomol. NMR, 20, 71-75.
101. Delaglio, F., Grzesiek, S., Vuister, G.W., Zhu, G., Pfeifer, J. and Bax, A. (1995) NMRPipe: a multidimensional spectral processing system based on UNIX pipes. J. Biomol. NMR, 6, 277-293.
102. Johnson, B.A. and Blevins, R.A. (1994) NMR view: a computer program for the visualization and analysis of NMRdata. J. Biomol.NMR, 4, 603-614.
103. Kjaergaard, M. and Poulsen, F.M. (2011) Sequence correction of random coil chemical shifts: correlation between neighbor correction factors and changes in the Ramachandran distribution. J. Biomol.NMR, 50, 157-165.
104. Steiner, P., Sarria, J.C., Glauser, L., Magnin, S., Catsicas, S. and Hirling, H. (2002) Modulation of receptor cycling by neuron-enriched endosomal protein of 21 kD. J. Cell. Biol., 157, 1197-1209.